Podium
Description
PP1
13:45 - 14:00

PATIENT PREFERENCES FOR HEALTH STATES FOLLOWING ALTERNATIVE MANAGEMENT OPTIONS FOR DUCTAL CARCINOMA IN SITU

Campbell BM1, Yang J2, Gonzalez JM2, Reed SD2, Havrilesky L3, Johnson FR2, Hwang ES3
1Duke University School of Medicine, Durham, NC, USA, 2Duke Clinical Research Institute, Durham, NC, USA, 3Duke Cancer Insitute, Durham, NC, USA

To view the podium abstract visit:
View Abstract

PP2
14:00 - 14:15

CHOICE DEFINES QALYS: A US VALUATION OF THE EQ-5D-5L

Craig BM1, Rand K2
1University of South Florida, and Assistant Member, Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA, 2University of Oslo, Oslo, Norway

To view the podium abstract visit:
View Abstract

PP3
14:15 - 14:30

ESTIMATING THE HEALTH STATE UTILITY OF PATIENTS WITH HER2– GBRCA+ METASTATIC BREAST CANCER TREATED WITH OLAPARIB OR CHEMOTHERAPY VIA A MAPPING ANALYSIS OF EORTC QLQ-C30 DATA COLLECTED IN THE OLYMPIAD CLINICAL TRIAL

Robson M1, Hettle R2, Degboe A3, Saunders O4, Cain T4, Kilvert H4, Johnson H4
1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2AstraZeneca, Cambridge, UK, 3AstraZeneca, Gaithersburg, MD, USA, 4Bresmed Ltd, Sheffield, UK

To view the podium abstract visit:
View Abstract

PP4
14:30 - 14:45

CONSUMER PREFERENCES FOR PRECISION MEDICINE TECHNOLOGIES: EVIDENCE FROM A DISCRETE CHOICE EXPERIMENT

Regier DA1, Veenstra DL2, Basu A3, Saha J2, Carlson JJ3
1BC Cancer/University of British Columbia, Vancouver, BC, Canada, 2Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA

To view the podium abstract visit:
View Abstract

Tags